July 22, 2026 — Shanghai MicroPort MedBot (Group) Co., Ltd. (HKEX: 02252, “MicroPort® MedBot™” or the “Group”) has issued a profit alert for the first half of 2026. According to the announcement, the Company expects to record an unaudited net profit of approximately RMB 28 million to RMB 40 million for the six months ended June 30, 2026.
This marks the Company's first-ever half-year profitability since its listing, representing a significant milestone in its operational performance and long-term development.
The Company's turnaround from a net loss to a net profit during the Reporting Period was primarily attributable to the following factors:
Substantial Revenue Growth
During the Reporting Period, the Group recorded a year-on-year revenue increase of approximately 200% to 230%.
Significant Improvement in Gross Profit Margin
The Group's overall gross profit margin increased by more than 15 percentage points compared with the same period last year.
Continued Optimisation of Expense Control
The Group continued to strengthen expense management and resource allocation, further improving overall operating efficiency.
-
2024-07-30MicroPort® MedBot®’s Real-time Fusion Fluorescence 3D Electronic Laparoscopic Imaging System Has Been Approved for Market Launch -
2024-04-03MicroPort® MedBot® Releases 2023 Annual Performance -
2023-09-28MicroPort®MedBot™ (02252.HK) Included in Hang Seng Artificial Intelligence Theme Index






Hu ICP Bei No. 20013662 HGWA Bei No. 31011502015178
" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd.” . They have been authorized to be used by Shanghai Microport Medbot (Group) Co., Ltd., and no other party shall use such trademarks without prior written permission thereof.
